191
Views
0
CrossRef citations to date
0
Altmetric
Articles

Constituents from Chloranthus multistachys and their cytotoxic activities against various human cancer cell lines

, , , , , , , & show all
Pages 330-341 | Received 27 Oct 2021, Accepted 17 Jun 2022, Published online: 05 Jul 2022
 

Abstract

Two new furanoeremophilane sesquiterpenoids, namely, 6,9-dioxo-1α,4α-dihydroxy-furanoeremophilane (1) and 4α,5α-epoxy-6,9-dioxo-1α-hydroxyl-furanoeremophilane (2), and 10 known compounds were isolated from the whole plant of Chloranthus multistachys, and compound 3 was converted to derivative 3a. Their structures were determined based on extensive spectroscopic analysis. All compounds were evaluated by using five cancer cell lines: PC3, LNcap, A549, K562, and HEL. The derivative 3a exhibited excellent cytotoxic activities, with the IC50 against HEL cells being the lowest at 1.322 ± 0.08 μM, which was comparable to that of the positive control (doxorubicin). Mechanism studies showed that the anticancer activity of 3a may be associated with cell cycle regulation.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was financially supported by the National Key Research and Development Program of China (2019YFC1712500); the Science and Social Development of Anshun City ([ASKS(2020)07], ASKP[2019]3); the Science and Technology Department of Guizhou Province (gzwjkj2019-1-190); the Science and Technology Department of Guizhou Province (QKHHBZ [2020]3003); and State Administration of GZTCM (QZYY-2020-088).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.